Drugs / AIC100
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04420754 | Sep 2020 → Aug 2026 overdue | poorly differentiated thyroid gland carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma | AffyImmune Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIC100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04420754 ↗ |
| Known as | AIC100 CAR T Cells | “The primary objective of this study is to assess the safety and tolerability of AIC100 CAR T Cells and determine the recommended Phase 2 dose of AIC100 in patients with...” NCT04420754 ↗ |
| Modality | Cell therapy | “The autologous T cells will be transfected and expanded in vitro to generate the AIC100 CAR T Cell product.” NCT04420754 ↗ |